Nowadays, a large number of people in the world are suffering from
chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7
HCV genotypes is considered to be the most promising target in combating HCV.
During the past decade, significant progress has been made in the discovery of
novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir
with high cure rates has been approved. Besides, quite a few nucleoside
anti-HCV agents are being evaluated in clinical trials. The purpose of this review
is to present recent progress in the development of nucleoside HCV NS5B polymerase
inhibitors, focusing on lead compounds that hold great promise for medicinal
use and their structure-activity relationships (SARs) in order to provide guidance
for future drug design and discovery.
Keywords: Hepatitis C virus, inhibitor, nucleoside, NS5B polymerase, prodrug, SAR.
Rights & PermissionsPrintExport